Skip to main
KALV

KalVista Pharma (KALV) Stock Forecast & Price Target

KalVista Pharma (KALV) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

KalVista Pharmaceuticals Inc. is experiencing robust demand for its FDA-approved product, EKTERLY (sebetralstat), which has generated $49 million in sales since its approval and is projected to achieve $170.8 million in sales by 2026, significantly higher than previous estimates. The positive outlook is bolstered by an increase in prescribers, growing from 423 to 580 by year-end 2025, along with strong refill rates indicating higher than anticipated market acceptance and utilization. Additionally, the market research indicating that only 65% of hereditary angioedema (HAE) attacks are currently treated with injectable therapies suggests substantial growth potential for EKTERLY as the on-demand HAE segment is projected to grow from $700 million to $1.5 billion.

Bears say

KalVista Pharmaceuticals faces a negative outlook primarily due to anticipated headwinds in the first quarter of 2026, linked to insurance reauthorizations and possibly elevated sales in prior periods influenced by year-end holiday demand. The company's revenue expectations for EKTERLY (sebetralstat) may not be met as a result of concerns regarding market size, penetration rates, and pricing, which pose significant risks to achieving projected sales. Additionally, the potential failure to secure adequate capital resources raises further uncertainty regarding the company's ability to finance operations and continue program development and commercialization activities.

KalVista Pharma (KALV) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of KalVista Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About KalVista Pharma (KALV) Forecast

Analysts have given KalVista Pharma (KALV) a Buy based on their latest research and market trends.

According to 6 analysts, KalVista Pharma (KALV) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

KalVista Pharma (KALV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.